Pharmacotherapy in sickle cell disease—state of the art and future prospects. (åbner nyt vindue)

Hankins J, Aygun B.

Kilde‎: Br J Haematol 2009;145(3):296-308.

Indekseret‎: PubMed 19222472

DOI‎: 10.1111/j.1365-2141.2009.07602.x

https://www.ncbi.nlm.nih.gov/pubmed/19222472 (åbner nyt vindue)

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. (åbner nyt vindue)

Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP, Wang WC.

Kilde‎: Blood 2005;106(7):2269-75.

Indekseret‎: PubMed 16172253

DOI‎: 10.1182/Blood-2004-12-4973

https://www.ncbi.nlm.nih.gov/pubmed/16172253 (åbner nyt vindue)

Hydroxyurea dose escalation for sickle cell anemia in sub-Saharan Africa. (åbner nyt vindue)

John CC, Opoka RO, Latham TS, Hume HA, Nabaggala C, Kasirye P, Ndugwa CM, Lane A, Ware RE

Kilde‎: N Engl J Med 2020;382(26):2524-33.

Indekseret‎: PubMed 32579813

DOI‎: 10.1056/NEJMoa2000146

https://www.ncbi.nlm.nih.gov/pubmed/32579813 (åbner nyt vindue)

The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. (åbner nyt vindue)

Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS.

Kilde‎: Br J Haematol 2013;161(6):852-60.

Indekseret‎: PubMed 23590693

DOI‎: 10.1111/bjh.12323

https://www.ncbi.nlm.nih.gov/pubmed/23590693 (åbner nyt vindue)

Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries. (åbner nyt vindue)

Mulaku M, Opiyo N, Karumbi J, Kitonyi G, Thoithi G, English M.

Kilde‎: Arch Dis Child 2013;98(11):908-14.

Indekseret‎: PubMed 23995076

DOI‎: 10.1136/archdischild-2012-302387

https://www.ncbi.nlm.nih.gov/pubmed/23995076 (åbner nyt vindue)

Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. (åbner nyt vindue)

Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB.

Kilde‎: Pediatrics 2008;122(6):1332-42.

Indekseret‎: PubMed 19047254

DOI‎: 10.1542/peds.2008-0441

https://www.ncbi.nlm.nih.gov/pubmed/19047254 (åbner nyt vindue)

Impact of hydroxyurea on clinical events in the BABY HUG trial. (åbner nyt vindue)

Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, Seaman P, Lebensburger J, Alvarez O, Thompson B, Ware RE, Wang WC; BABY HUG Investigators.

Kilde‎: Blood 2012;120(22):4304-10.

Indekseret‎: PubMed 22915643

DOI‎: 10.1182/blood-2012-03-419879

https://www.ncbi.nlm.nih.gov/pubmed/22915643 (åbner nyt vindue)

Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa. (åbner nyt vindue)

Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, Aygun B, Stuber SE, Latham TS, McGann PT, Ware RE; REACH Investigators

Kilde‎: N Engl J Med 2019;380(2):121-31.

Indekseret‎: PubMed 30501550

DOI‎: 10.1056/NEJMoa1813598

https://www.ncbi.nlm.nih.gov/pubmed/30501550 (åbner nyt vindue)

Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. (åbner nyt vindue)

Wang WC, Helms RW, Lynn HS, Redding-Lallinger R, Gee BE, Ohene-Frempong K, Smith-Whitley K, Waclawiw MA, Vichinsky EP, Styles LA, Ware RE, Kinney TR.

Kilde‎: J Pediatr 2002;140(2):225-9.

Indekseret‎: PubMed 11865275

DOI‎: 10.1067/mpd.2002.121383

https://www.ncbi.nlm.nih.gov/pubmed/11865275 (åbner nyt vindue)

Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. (åbner nyt vindue)

Wang WC, Oyeku SO, Luo Z, Boulet SL, Miller ST, Casella JF, Fish B, Thompson BW, Grosse SD; BABY HUG Investigators.

Kilde‎: Pediatrics 2013;132(4):677-83.

Indekseret‎: PubMed 23999955

DOI‎: 10.1542/peds.2013-0333

https://www.ncbi.nlm.nih.gov/pubmed/23999955 (åbner nyt vindue)

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). (åbner nyt vindue)

Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; for the BABY HUG investigators.

Kilde‎: Lancet 2011;377(9778):1663-72.

Indekseret‎: PubMed 21571150

DOI‎: 10.1016/S0140-6736(11)60355-3

https://www.ncbi.nlm.nih.gov/pubmed/21571150 (åbner nyt vindue)

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. (åbner nyt vindue)

Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NL, Cohen AR, Pressel S, Adams RJ.

Kilde‎: Lancet 2016;387(10019):661-70.

Indekseret‎: PubMed 26670617

https://www.ncbi.nlm.nih.gov/pubmed/26670617 (åbner nyt vindue)

How I use hydroxyurea to treat young patients with sickle cell anemia. (åbner nyt vindue)

Ware RE.

Kilde‎: Blood 2010;115(26):5300-11.

Indekseret‎: PubMed 20223921

DOI‎: 10.1182/blood-2009-04-146852

https://www.ncbi.nlm.nih.gov/pubmed/20223921 (åbner nyt vindue)

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. (åbner nyt vindue)

Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.

Kilde‎: Blood 2004;103(6):2039-45.

Indekseret‎: PubMed 14630791

DOI‎: 10.1182/blood-2003-07-2475

https://www.ncbi.nlm.nih.gov/pubmed/14630791 (åbner nyt vindue)

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. (åbner nyt vindue)

Hirst C, Owusu-Ofori S.

Kilde‎: Cochrane Database Syst Rev 2012;(9):CD003427.

Indekseret‎: PubMed 22972063

DOI‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 (åbner nyt vindue)

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. (åbner nyt vindue)

Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E

Kilde‎: Lancet Haematol 2021;8(5):e323-33.

Indekseret‎: PubMed 33838113

DOI‎: 10.1016/S2352-3026(21)00059-4

https://www.ncbi.nlm.nih.gov/pubmed/33838113 (åbner nyt vindue)

Sickle cell disease. (åbner nyt vindue)

Meremikwu MM, Okomo U.

Kilde‎: BMJ Clin Evid 2011;02:2402.

Indekseret‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 (åbner nyt vindue)

A phase 3 trial of l-glutamine in sickle cell disease. (åbner nyt vindue)

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

Kilde‎: N Engl J Med 2018;379(3):226-35.

Indekseret‎: PubMed 30021096

DOI‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 (åbner nyt vindue)

Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. (åbner nyt vindue)

Olupot-Olupot P, Tomlinson G, Williams TN, Tshilolo L, Santos B, Smart LR, McElhinney K, Howard TA, Aygun B, Stuber SE, Lane A, Latham TS, Ware RE

Kilde‎: Blood. 2023 23;141(12):1402-10.

Indekseret‎: PubMed 36375125

DOI‎: 10.1182/blood.2022017051

https://pubmed.ncbi.nlm.nih.gov/36375125/ (åbner nyt vindue)

Malaria chemoprophylaxis in sickle cell disease. (åbner nyt vindue)

Oniyangi O, Omari AA.

Kilde‎: Cochrane Database Syst Rev 2006;(4):CD003489.

Indekseret‎: PubMed 17054173

DOI‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 (åbner nyt vindue)